Attovia Therapeutics
ATTO · Nasdaq · United States
Share price · ATTO
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ATTO's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
No unusual moves in the past 12 months.
Share of unusual movement by asset
For each asset, the share of ATTO's own-move activity since 6 Aug 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
ATTO-1310events and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 1% |
| Other company news (earnings, financing, releases naming no asset) | — | 9% |
| Sessions with no dated event | — | 89% |
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | IL-31Biologic (subtype unspecified) | Atopic Dermatitis |
Discontinued programmes (1)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
What to watch
Financial reports
Quarterly & interim (4)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $20M | $116M+ $281M short-term inv. | $22M-$26M operating cash flow | report ↗ |
View 3 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0.5M | $19M | $33M+ $82M short-term inv. | $21M | report ↗ |
| 2025-Q3 | $0.4M | $12M | $50M | $14M-$15M operating cash flow | report ↗ |
| 2025-Q2 | $0 | $14M | $43M | $14M | report ↗ |
Annual history (2 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | — | $41M+ $112M short-term inv. | — | report ↗ |
View 1 more year
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | — | $31M | — | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 13 purchases ($72.9M), 92 sales ($9.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-08-06 | GOLDMAN SACHS GROUP INC; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P. · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner | Conversion | 1,957,134 | — | — | Form 4 |
| 2026-08-06 | WALSH COLIN · director | Conversion | 1,957,134 | — | — | Form 4 |
| 2026-08-06 | GOLDMAN SACHS GROUP INC; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P. · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner | Conversion | 478,498 | — | — | Form 4 |
| 2026-08-06 | WALSH COLIN · director | Conversion | 478,498 | — | — | Form 4 |
| 2026-08-06 | GOLDMAN SACHS GROUP INC; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P. · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner | Open-market purchase | 500,000 | $17.00 | $8.5M | Form 4 |
| 2026-08-06 | WALSH COLIN · director | Open-market purchase | 500,000 | $17.00 | $8.5M | Form 4 |
| 2026-08-06 | GOLDMAN SACHS GROUP INC; GOLDMAN SACHS & CO. LLC; GOLDMAN SACHS ASSET MANAGEMENT, L.P.; Broad Street Principal Investments, L.L.C.; WSLS OFFSHORE INVESTMENTS, SLP; West Street Life Sciences I, L.P.; WSLS EMP OFFSHORE INVESTMENTS, L.P.; WSLS EMP ONSHORE INVESTMENTS, L.P. · Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner; Former 10% Owner | Conversion (derivative) | 18,181,830 | — | — | Form 4 |
| 2026-08-06 | WALSH COLIN · director | Conversion (derivative) | 18,181,830 | — | — | Form 4 |